1. Pink Sheet

Samsung's Biosimilar Manufacturing Documents Lead Janssen To Drop Infringement Suit

 
• By Brenda Sandburg

Janssen concludes the manufacturing processes for Renflexis do not infringe its Remicade patents, clearing Samsung and partner Merck from potential damages resulting from their at-risk launch of the biosimilar; innovator's legal action remains against Inflectra partners Pfizer and Celltrion.

court house

Janssen Biotech Inc.'s dismissal of its suit against Samsung Bioepis Co. Ltd. is good news for biosimilar sponsors as it shows they can defeat claims that their manufacturing processes infringe an innovator's patents.

Janssen dropped the complaint on Nov

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Biosimilars & Generics